|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 2/01/22 Bionovate Technologies Corp. 8-K:8 7/13/21 12:127K Pubco Reporting … Inc/FA |
Document/Exhibit Description Pages Size 1: 8-K Current Report HTML 20K 7: R1 Cover HTML 43K 10: XML IDEA XML File -- Filing Summary XML 12K 8: XML XBRL Instance -- biio_8k_htm XML 14K 9: EXCEL IDEA Workbook of Financial Reports XLSX 6K 4: EX-101.CAL XBRL Calculations -- biio-20210713_cal XML 7K 6: EX-101.DEF XBRL Definitions -- biio-20210713_def XML 10K 3: EX-101.LAB XBRL Labels -- biio-20210713_lab XML 41K 5: EX-101.PRE XBRL Presentations -- biio-20210713_pre XML 27K 2: EX-101.SCH XBRL Schema -- biio-20210713 XSD 19K 11: JSON XBRL Instance as JSON Data -- MetaLinks 11± 16K 12: ZIP XBRL Zipped Folder -- 0001640334-22-000222-xbrl Zip 9K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM i 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) i July 13, 2021
i BIONOVATE TECHNOLOGIES CORP. |
(Exact name of registrant as specified in its charter) |
i Nevada |
|
| i 33-1229553 | |
(State or other jurisdiction of incorporation) |
| (Commission File Number) |
| (IRS Employer Identification No.) |
i Gewerbestrasse 1, i Cham, i Switzerland |
| i 6330 |
(Address of principal executive offices) |
| (Zip Code) |
Registrant’s telephone number, including area code i 280- i 231-1606
______________________________________________
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
i ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
i ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
i ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
i ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company i ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. i ☐
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
None | None | None |
Item 8.01 Other Events.
On July 13, 2021, Aleksander Vucak ("Vucak") was reappointed as a director and as an officer for our company. The company decided that Timothy Jones ("Jones") appointment was not necessary. This decision was not a result of a disagreement between Jones and the company; nor any matter relating to the company's operations, policies, or practices. Item 12. Results of Operations and Financial Condition.
There are no family relationship between Vucak and any director or executive officer of our company and no related party transactions required to be reported under the Item 404(a) of Regulations S-K
| 2 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
/s/ Aleksander Vucak | |
| |
Date: January 31, 2022 |
3 |
| This ‘8-K’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 2/1/22 | None on these Dates | ||
| 1/31/22 | ||||
| For Period end: | 7/13/21 | |||
| List all Filings | ||||